Loading organizations...
Based in Uruguay, Antarka is a biotechnology company that develops and supplies a skin-permeable enzyme derived from Antarctic microbes to actively repair UV-induced DNA damage in human skin cells. Operating as a B2B cosmetic ingredient supplier, the enterprise licenses its proprietary technology to global beauty brands for incorporation into anti-aging skincare formulations targeting both cyclobutane pyrimidine dimers and 6-4 photoproducts to reverse fine lines and dark marks. Following its participation in the IndieBio SF 16 accelerator program, the organization secured licensing agreements with five key strategic partners within a four-month period. The company has achieved Good Manufacturing Practice alignment and currently maintains a production capacity of 300,000 units per month to support immediate product commercialization and initial inventory buildup. Antarka was founded by biotechnology researchers Stefano Valdesolo, Juan Jose Marizcurrena, Betania Martinez, and Celica Cagide.
Antarka has raised $35.0M across 1 funding round.
Antarka has raised $35.0M in total across 1 funding round.
Antarka has raised $35.0M across 1 funding round. Most recently, it raised $35.0M Seed in March 2026.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Mar 17, 2026 | $35M Seed | Natura Ventures, Zentynel Frontier Investments | CTK, GS Futures, SOSV | Announced |
Antarka has raised $35.0M in total across 1 funding round.
Antarka's investors include Natura Ventures, Zentynel Frontier Investments, CTK, GS Futures, SOSV.
